Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.1000
- TODAY'S CHANGE (%)0.0900 (2.9900%)
- Bid / Lots3.0800/ 5
- Ask / Lots3.1800/ 70
- Open / Previous Close2.9900 / 3.0100
- Day Range
- 52 Week Range
- Volume541,270
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 2832 | 2.94 |
| 09:34 ET | 610 | 2.9589 |
| 09:36 ET | 1312 | 2.96 |
| 09:38 ET | 500 | 2.9734 |
| 09:39 ET | 900 | 2.985 |
| 09:41 ET | 700 | 3.005 |
| 09:43 ET | 2695 | 2.995 |
| 09:45 ET | 800 | 2.987 |
| 09:48 ET | 100 | 2.99 |
| 09:50 ET | 2080 | 3 |
| 09:52 ET | 7045 | 2.995 |
| 09:54 ET | 200 | 2.99 |
| 09:56 ET | 5500 | 2.985 |
| 09:59 ET | 1800 | 2.995 |
| 10:01 ET | 1000 | 2.995 |
| 10:03 ET | 100 | 2.9901 |
| 10:06 ET | 100 | 3 |
| 10:08 ET | 3840 | 2.9901 |
| 10:10 ET | 7916 | 3.02 |
| 10:12 ET | 451 | 3.025 |
| 10:14 ET | 3777 | 3.0002 |
| 10:15 ET | 500 | 3.0004 |
| 10:19 ET | 100 | 2.99 |
| 10:21 ET | 200 | 3 |
| 10:24 ET | 208 | 3 |
| 10:28 ET | 100 | 3.01 |
| 10:30 ET | 226 | 3.01 |
| 10:33 ET | 818 | 3.01 |
| 10:37 ET | 226 | 3.01 |
| 10:42 ET | 100 | 3.01 |
| 10:44 ET | 700 | 3.005 |
| 10:46 ET | 200 | 3.01 |
| 10:50 ET | 100 | 3.01 |
| 10:51 ET | 100 | 3.0099 |
| 10:55 ET | 2658 | 2.98 |
| 10:57 ET | 100 | 2.98 |
| 11:06 ET | 1000 | 2.9799 |
| 11:08 ET | 100 | 2.98 |
| 11:09 ET | 200 | 2.975 |
| 11:11 ET | 100 | 2.98 |
| 11:13 ET | 250 | 2.97 |
| 11:15 ET | 20143 | 3.015 |
| 11:18 ET | 2661 | 3.01 |
| 11:20 ET | 7007 | 3.045 |
| 11:22 ET | 100 | 3.05 |
| 11:24 ET | 467 | 3.0407 |
| 11:26 ET | 13213 | 3.0599 |
| 11:27 ET | 11921 | 3.045 |
| 11:29 ET | 1516 | 3.04 |
| 11:36 ET | 375 | 3.0396 |
| 11:40 ET | 2300 | 3.06 |
| 11:42 ET | 1500 | 3.055 |
| 11:44 ET | 100 | 3.055 |
| 11:45 ET | 500 | 3.05 |
| 11:47 ET | 3071 | 3.06 |
| 11:49 ET | 400 | 3.065 |
| 11:51 ET | 4014 | 3.068 |
| 11:54 ET | 1700 | 3.065 |
| 11:58 ET | 7728 | 3.06 |
| 12:00 ET | 1710 | 3.07 |
| 12:02 ET | 200 | 3.08 |
| 12:03 ET | 2600 | 3.08 |
| 12:09 ET | 1200 | 3.08 |
| 12:12 ET | 1500 | 3.0775 |
| 12:14 ET | 100 | 3.08 |
| 12:18 ET | 410 | 3.08 |
| 12:20 ET | 360 | 3.0799 |
| 12:21 ET | 1950 | 3.0709 |
| 12:23 ET | 1752 | 3.07 |
| 12:25 ET | 925 | 3.0799 |
| 12:27 ET | 207 | 3.075 |
| 12:30 ET | 100 | 3.08 |
| 12:32 ET | 855 | 3.08 |
| 12:34 ET | 845 | 3.08 |
| 12:36 ET | 7237 | 3.08 |
| 12:38 ET | 325 | 3.08 |
| 12:41 ET | 795 | 3.087 |
| 12:48 ET | 200 | 3.085 |
| 12:50 ET | 11897 | 3.075 |
| 12:52 ET | 2070 | 3.06 |
| 12:54 ET | 2510 | 3.06 |
| 12:57 ET | 2947 | 3.055 |
| 01:01 ET | 2803 | 3.05 |
| 01:08 ET | 1782 | 3.06 |
| 01:12 ET | 673 | 3.0505 |
| 01:15 ET | 100 | 3.06 |
| 01:17 ET | 1000 | 3.0508 |
| 01:19 ET | 3242 | 3.05 |
| 01:21 ET | 100 | 3.06 |
| 01:24 ET | 1050 | 3.05 |
| 01:35 ET | 9222 | 3.05 |
| 01:39 ET | 100 | 3.05 |
| 01:42 ET | 2010 | 3.06 |
| 01:44 ET | 100 | 3.06 |
| 01:50 ET | 710 | 3.055 |
| 01:51 ET | 300 | 3.058 |
| 01:53 ET | 2500 | 3.06 |
| 01:55 ET | 220 | 3.06 |
| 02:00 ET | 100 | 3.055 |
| 02:02 ET | 800 | 3.055 |
| 02:08 ET | 100 | 3.055 |
| 02:13 ET | 1200 | 3.05 |
| 02:15 ET | 890 | 3.055 |
| 02:18 ET | 200 | 3.055 |
| 02:24 ET | 100 | 3.06 |
| 02:26 ET | 100 | 3.06 |
| 02:27 ET | 679 | 3.06 |
| 02:33 ET | 900 | 3.08 |
| 02:36 ET | 300 | 3.075 |
| 02:38 ET | 7321 | 3.08 |
| 02:40 ET | 100 | 3.09 |
| 02:44 ET | 100 | 3.09 |
| 02:47 ET | 5640 | 3.06 |
| 02:54 ET | 24372 | 3.05 |
| 02:56 ET | 2106 | 3.04 |
| 02:58 ET | 733 | 3.035 |
| 03:00 ET | 890 | 3.034 |
| 03:02 ET | 3132 | 3.045 |
| 03:03 ET | 27258 | 3.0499 |
| 03:05 ET | 18808 | 3.05 |
| 03:09 ET | 5171 | 3.04 |
| 03:12 ET | 300 | 3.035 |
| 03:14 ET | 2200 | 3.035 |
| 03:16 ET | 2760 | 3.05 |
| 03:18 ET | 2250 | 3.06 |
| 03:20 ET | 26932 | 3.0799 |
| 03:21 ET | 14875 | 3.085 |
| 03:23 ET | 1800 | 3.09 |
| 03:25 ET | 5288 | 3.09 |
| 03:27 ET | 1107 | 3.09 |
| 03:30 ET | 1100 | 3.09 |
| 03:32 ET | 2150 | 3.09 |
| 03:34 ET | 1588 | 3.09 |
| 03:36 ET | 1856 | 3.09 |
| 03:38 ET | 1950 | 3.09 |
| 03:39 ET | 8840 | 3.095 |
| 03:41 ET | 27396 | 3.105 |
| 03:43 ET | 7744 | 3.105 |
| 03:45 ET | 2860 | 3.11 |
| 03:48 ET | 900 | 3.11 |
| 03:50 ET | 3124 | 3.1 |
| 03:52 ET | 6744 | 3.12 |
| 03:54 ET | 3988 | 3.12 |
| 03:56 ET | 17904 | 3.125 |
| 03:57 ET | 8715 | 3.115 |
| 03:59 ET | 7745 | 3.1 |
Apr 10, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham, from 6:21AM ET on Wednesday Apr 10, 2024 by Dow Jones
6:21AM ET on Wednesday Apr 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 422.2M | -11.9x | --- |
Celcuity Inc | 539.0M | -6.5x | --- |
Larimar Therapeutics Inc | 518.7M | -9.4x | --- |
Kalvista Pharmaceuticals Inc | 514.3M | -3.8x | --- |
Altimmune Inc | 515.4M | -4.4x | --- |
Astria Therapeutics Inc | 548.0M | -4.1x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $422.2M |
|---|---|
Revenue (TTM) | $8.9M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-0.26 |
Book Value | $0.62 |
P/E Ratio | -11.9x |
Price/Sales (TTM) | 47.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
